Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 Commission File Number: 001-39059 AVITA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 85-1021707 (State or other jur ...

AVITA Therapeutics, Inc. (NASDAQ:RCEL) Q2 2021 Earnings Conference Call February 11, 2021 4:30 PM ET Company Participants Caroline Corner - Investor Relations, Westwicke Mike Perry - Chief Executive Officer Sean Ekins - Interim Principal Financial Officer and Accounting Officer Erin Liberto - Chief Commercial Officer Andrew Quick - Chief Technology Officer Conference Call Participants Josh Jennings - Cowen Kevin DeGeeter - Oppenheimer & Co Ryan Zimmerman - BTIG Brooks O'Neil - Lake Street Capital Markets Ly ...

AVITA Therapeutics, Inc. (NASDAQ:RCEL) Q1 2021 Earnings Conference Call November 10, 2020 4:30 PM ET Company Participants Caroline Corner - Westwicke Partners, Managing Director Michael Perry - Chief Executive Officer Sean Ekins - Vice President, Finance Conference Call Participants Josh Jennings - Cowen Ryan Zimmerman - BTIG Kevin DeGeeter - Oppenheimer Brooks O'Neil - Lake Street Capital John Hester - Bell Potter Lyanne Harrison - Bank of America Operator Ladies and gentlemen, thank you for standing by an ...

AVITA Therapeutics, Inc. (NASDAQ:RCEL) Q3 2020 Earnings Conference Call November 10, 2020 4:20 PM ET Company Participants Caroline Corner - Managing Director Michael Perry - Chief Executive Officer Sean Ekins - Vice President of Finance Conference Call Participants Josh Jennings - Cowen Ryan Zimmerman - BTIG Kevin DeGeeter - Oppenheimer Brooks O'Neil - Lake Street Capital Markets Lyanne Harrison - Bank of America Merrill Lynch Disclaimer: *NEW* We are providing this transcript version in a raw, machine-assi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39059 AVITA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 85-1021707 (State or ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39059 AVITA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 85-1021707 (State or other jurisdi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION ...